Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Neuroimage|May 14, 2013
Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10AS Celen, M Koole, M Ooms, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2000
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinomaP Flamen, A Lerut, E Van Cutsem, et al.Human Mutation|August 19, 2006
Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragmentJ Theuns, E Marjaux, M Vandenbulcke, et al.Journal of Clinical Research in Pediatric Endocrinology|August 8, 2024
Experience in a PTEN Hamartoma Tumor Syndrome Expertise Centre: Yield of Thyroid Ultrasound Surveillance in Children with PTEN Hamartoma Tumor SyndromeEsther M G Bormans, Janneke H M Schuurs-Hoeijmakers, Petra van Setten, et al.International Journal of Surgery (London, England)|June 8, 2023
Variation in the management of adhesive small bowel obstruction in the Netherlands: a prospective cross-sectional studyPepijn Krielen, Lisa P A Kranenburg, Martijn W J Stommel, et al.Journal of Psychopharmacology (Oxford, England)|February 12, 2010
MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humansJ R Atack, K A Wafford, L J Street, et al.Clinical Pharmacology and Therapeutics|June 29, 2012
Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imagingK Van Laere, J De Hoon, G Bormans, et al.Journal of Psychopharmacology (Oxford, England)|February 17, 2010
Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonistJ R Atack, D J Hallett, S Tye, et al.Pageof 6